Hep 3B In Vitro Comparative Genomic Hybridization (CGH) Assay
CAT#: ITS-1022-YF2182
Target Cell Organism: Human
Target Cell Alternative Name: Hep-3B; Hep3B; Hep 3B2.1-7
Target Cell Name: Hep 3B
Assay Type: Genome Alteration Assays
Assay Overview
This assay is to provide Hep 3B-based In Vitro Comparative Genomic Hybridization (CGH) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.
Target Cell Name
Hep 3B
Target Cell Organism
Human
Target Cell Background
Hep 3B is a cell line exhibiting epithelial morphology that was isolated from liver tissue derived from an 8-year-old, Black youth with liver cancer. This cell line contains an integrated hepatitis B virus genome.
Target Cell Alternative Name
Hep-3B; Hep3B; Hep 3B2.1-7
Related Diseases
Hepatocellular Carcinoma
Research Area
Oncology
Assay Name
In Vitro Comparative Genomic Hybridization (CGH) Assay
Short Description
Hep 3B-cell based In Vitro Comparative Genomic Hybridization (CGH) Assay
Assay Description
CGH is another popular cytogenetic technique, which is used to analyze copy number variations in genomes. In this technique, DNA in the reference sample (tumors) is first labeled with fluorochromes and allowed to hybridize with normal DNA. Human Cot-1 DNA is used to inhibit non-specific hybridization in this technique. Analyzing the ratio between fluorescence signal intensities of labeled DNA in samples and references can be plotted for each chromosome, permitting identification of possible copy number changes. CGH does not give much information about gene dosages and it is reported to be insensitive to structural abnormalities where copy number is not altered.
Assay Type
Genome Alteration Assays
Assay Type Details
Aberrant or somatic mutations are more commonly found in the DNA of cancer cells compared to normal cells. There is an equilibrium that exists between DNA damage and repair in normal cells. However, in cancer cells these events are disturbed, resulting in mutations and genomic instability. Genomic instability in cancer cells causes chromosomal aberrations, microsatellite instability, aneuploidy and uncontrolled gene amplifications and genetic instability in cancer cells are mainly due to point mutations or chromosomal aberrations such as insertions, deletions and translocation, resulting in mutated proteins.